AKTX logo

AKARI THERAPEUTICS PLC-ADR

AKTXNASDAQ
🏆 #4626 by market capEarnings Nov 11US Equity
$8.46▼ $1.11 (−11.65%)
Pre-market · at close
🔔
Track AKTX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 11.7%
7d▼ 11.7%
14d▲ 15.0%
30d▼ 15.7%
ytd▼ 25.8%
1y▼ 72.2%
🏦Market Cap
$19M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$8.21 – $8.46
52-Week Range
$3.02 – $33.60
Volume (shares)
1,193
Avg Volume (shares)
—
Shares Outstanding
2.3M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-0.0
P/S Ratio
0.0x
EPS (TTM)
$-17.28
Dividend Yield
0.00%
Dilution (1yr)
+116.8%
AKTX logo

AKARI THERAPEUTICS PLC-ADR

AKTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$17M▼ −20.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▼ −15.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
21K▲ +116.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▲ +$5M YoY
StockOtter · stockotter.space

About AKARI THERAPEUTICS PLC-ADR

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.